Table 3.
Baseline Characteristics of Patients with and without HBV Markers in Serum
| Anti-HBc+ (N=121) | Anti-HBc− (N=152) | P-value* | |||||
|---|---|---|---|---|---|---|---|
| Anti-HBs− (N=60) | Anti-HBs+ (N=61) | ||||||
| Mean/% | SD | Mean/% | SD | Mean/% | SD | ||
| Demographics | |||||||
| Age, years | 50.4 | 5.59 | 51.8 | 7.38 | 51.1 | 8.01 | 0.96 |
| Gender, male | 83.3% | 73.8% | 71.1% | 0.16 | |||
| Race | 0.09 | ||||||
| White | 70.0% | 60.7% | 74.3% | ||||
| Hispanic | 5.0% | 9.8% | 10.5% | ||||
| Black | 23.3% | 24.6% | 13.8% | ||||
| Other | 1.7% | 4.9% | 1.3% | ||||
| Labs | |||||||
| Platelet, × 1000/mm3 | 150.4 | 53.5 | 141.4 | 47.1 | 153.4 | 66.7 | 0.30 |
| Albumin, g/dL | 3.77 | 0.44 | 3.74 | 0.39 | 3.88 | 0.44 | 0.02 |
| AST, U/L | 110.2 | 83.6 | 91.6 | 44.4 | 96.1 | 67.2 | 0.57 |
| ALT, U/L | 126.8 | 105.4 | 110.2 | 63.0 | 114.1 | 92.3 | 0.69 |
| Alkaline phosphatase, U/L | 112.6 | 65.4 | 111.1 | 54.4 | 105.3 | 48.0 | 0.32 |
| T bilirubin, mg/dL | 0.81 | 0.35 | 0.83 | 0.34 | 0.85 | 0.46 | 0.57 |
| INR | 1.07 | 0.11 | 1.06 | 0.11 | 1.05 | 0.13 | 0.17 |
| AFP, ng/mL | 19.0 | 31.9 | 23.4 | 36.4 | 16.8 | 21.1 | 0.20 |
| Cirrhosis | 60.0% | 49.2% | 56.6% | 0.74 | |||
| Maintenance peginterferon | 44.1% | 54.1% | 42.3% | 0.26 | |||
| Esophageal varices | 33.9% | 33.3% | 32.4% | 0.84 | |||
| Risk factors | |||||||
| Transfusion of blood or blood products | 33.9% | 32.8% | 45.7% | 0.04 | |||
| Occupational exposure | 23.3% | 26.2% | 23.8% | 0.86 | |||
| Tattoo | 33.3% | 41.0% | 26.3% | 0.054 | |||
| Body piercing | 0.0% | 4.9% | 0.0% | 0.09 | |||
| Injected recreational drugs | 63.3% | 52.5% | 33.5% | <.0001 | |||
| Snorted cocaine | 73.3% | 57.4% | 46.1% | 0.002 | |||
*
P-value for comparison of 121 anti-HBc+ vs. 152 anti-HBc- patients